Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic Stroke

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic Stroke

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reteplase (Primary) ; Alteplase
  • Indications Ischaemic stroke
  • Focus Registrational; Therapeutic Use
  • Sponsors Angde Biotech Pharmaceutical

Most Recent Events

  • 29 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 14 Apr 2023 Planned End Date changed from 1 May 2023 to 1 Jun 2023.
  • 14 Apr 2023 Planned primary completion date changed from 1 May 2023 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top